Investors might want to bet on Foghorn Therapeutics Inc. (FHTX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Th ...

Core Viewpoint - Foghorn Therapeutics Inc. (FHTX) shows significant upside potential with a mean price target of $16, indicating a 104.1% increase from its current price of $7.84 [1] Price Target Analysis - The mean estimate consists of six short-term price targets with a standard deviation of $4.34, suggesting variability in analyst predictions. The lowest estimate of $9 indicates a 14.8% increase, while the highest target of $20 suggests a 155.1% increase [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - There is growing optimism among analysts regarding FHTX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 11.2% over the past month, with four estimates rising and no negative revisions [9][10] - FHTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading. Analysts may set overly optimistic targets due to business incentives, which can inflate expectations [5][6] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions, as this could lead to disappointing returns [8]

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][4] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate potential drug targets within the chromatin regulatory system, which has the potential to transform treatment options for a wide range of diseases [1][4] Conference Participation - Foghorn management will participate in the Jefferies London Healthcare Conference on November 19, 2024, with a fireside chat led by CEO Adrian Gottschalk [2] - The company will also engage in one-on-one meetings during the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and the Citi Global Healthcare Conference on December 4, 2024 [3][2] Company Overview - Foghorn Therapeutics is dedicated to discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, with multiple product candidates currently in development for oncology [4]

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.19%. A quarter ago, it was expected that this company would post a loss of $0.60 per share when it actually produced a loss of $0.45, delivering a surprise of 25%.Over the last four quarters, the company has s ...

Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $8.28, gaining 35.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15 indicates an 81.2% upside potential. The average comprises five short-term price targets ranging from a low of $6 to a high of $20, with a standard deviation of $5.83. While the lowest estimate indicates a decline of 27.5% from the current pri ...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline ...

Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $6.20, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.75 indicates a 121.8% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $5.91. While the lowest estimate of $6 indicates a 3.2% decline from the current price level, the most optimistic ana ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.59, delivering a surprise of -7.27%. Over the last four quarters, the company has ...

Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain ...

The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computat ...